Board of Directors

Eight directors with extensive experiences in science and medicine, industry and venture capital currently serve on the Argos Board to provide strategic direction to the company.

Clint G. Dederick, Jr., M.B.A. Chairman & CEO,
Argos Therapeutics
Chairman of the Board
Hubert Birner, Ph.D., M.B.A. TVM Director
B. Jefferson (Jeff) Clark, M.B.A. Aurora Funds Director
Eli Gilboa, Ph.D. Scientific Founder,
Argos Therapeutics
Director
Michel Gréco, M.B.A.
Aventis
Director
Richard Meadows CDP Capital Director
Philip R. (Phil) Tracy, J.D. Intersouth Director
Brian J. Underdown, Ph.D. MDS Capital Director
Sander van Deventer, M.D., Ph.D. AMC/ABN AMRO Director


Clint G. Dederick, Jr., M.B.A.

Chairman of the Board, CEO and President
Clint Dederick brings over 30 years of experience in the pharmaceutical and biotechnology industries to Argos Therapeutics. He has served as chairman of the board for 3 years since the company’s inception. Dederick was group director, venture projects, of Senmed Medical Ventures for 15 years prior to becoming CEO and president of Argos in 2002. He also served on the boards of several companies during his tenure with Senmed. Prior to joining Senmed, Dederick worked with Praxis Biologics, Inc., Seragen, Inc., and Collaborative Research, Inc. He also worked with Eli Lilly & Co., where he was engaged with a variety of domestic and international assignments over a period of ten years. Dederick’s academic background includes an undergraduate degree from the University of Delaware in biology and chemistry, and a M.B.A. from the University of Virginia Darden School.
return to top

Hubert Birner, Ph.D. M.B.A.
Director
Hubert Birner is a partner with TVM and joined that organization in October 2000. He is vice chairman of the board of Direvo Biotech AG (Cologne). Previously, he held senior management positions at AstraZeneca's agribusiness division (now known as Syngenta) as Head of Business Development, Europe, and Director of Marketing, Germany. Birner joined AstraZeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a consultant, he gained extensive experience in R&D management, marketing & sales as well as joint venture structuring and business development. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. He holds an M.B.A. from Harvard Business School and a summa cum laude doctoral degree in biochemistry from Ludwig-Maximilians-University Munich. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding fundamental research in metabolic diseases.
return to top

B. Jefferson (Jeff) Clark, M.B.A.
Director
B. Jefferson Clark co-founded The Aurora Funds, Inc. (Aurora) in 1994 and is currently General Partner responsible for life science investments in Aurora’s three existing funds, which encompass in excess of $72 million. Prior to forming Aurora, Clark worked in development and external affairs for Duke University. Clark has extensive strategic planning and operational experience and has overseen more than a dozen life science investments since 1995. He presently serves on the boards of seven of Aurora’s life science portfolio companies, including Insect Biotechnology, Inc., Argos Therapeutics, Inc., Norak Biosciences, VetCentric, Peracom, TriVirix International, and United Emergency Services, assisting in the strategic direction of each. Clark also serves on the board of directors of the Duke Comprehensive Cancer Center and the Council for Entrepreneurial Development. Clark holds a B.S. in mechanical engineering from Duke University and an M.B.A. from the Fuqua School of Business at Duke University.
return to top

Eli Gilboa, Ph.D.
Director
Eli Gilboa is scientific founder and chairman of the scientific advisory board and serves as acting chief scientific officer for Argos Therapeutics. Gilboa is a co-inventor of the Company’s core therapeutic vaccine technology; an expert in immunology, molecular biology and immunotherapy; and an early pioneer in the gene therapy field. He is currently Director of the Center for Genetic and Cellular Therapies at Duke University Medical Center. He is also a Joseph and Dorothy Beard Professor of Experimental Surgery and Immunology, Departments of Surgery and Immunology, Duke University Medical Center. Gilboa served as an Associate Member of the Sloan Kettering Institute for Cancer Research Molecular Biology Program from 1986 to 1993. He was Assistant Professor in the Department of Molecular Biology at Princeton University from 1980 to 1986. He graduated in 1971 from Hebrew University, Jerusalem, Israel with a B.S. in biochemistry. Gilboa received his Ph.D. in molecular biology at the Weizmann Institute, Rehovot, Israel in 1977.
return to top

Michel Gréco, M.B.A.
Director
Michel Gréco has vast experience in healthcare field and vaccine research. He is a board member of several public and private companies and international institutions, and advisor to the World Health Organization.

Gréco began his career with Theraplix, a pharmaceutical subsidiary of the French Group Rhône Poulenc in 1968. In 1975, he was appointed Vice President for Commercial Operations, France and International. In 1982, Gréco moved to Rhône Poulenc’s Health Division as Vice President Strategy, in charge of Corporate Marketing. In 1987, he joined another Rhône Poulenc subsidiary, "Institut Mérieux Human Health", a leading vaccine company based in Lyon France. There, he was appointed Deputy General Manager in 1988. Gréco has participated in the successive acquisitions of Pasteur Vaccins (the Vaccine arm of Institut Pasteur) and Connaught Laboratories (in the United States and Canada) and became Vice President Europe of the new company (Pasteur Mérieux Connaught). Gréco was deputy CEO and member of the Board of Aventis Pasteur until January 2003. Since leaving Aventis, Gréco has been a board member of Powderject (UK) and was instrumental in its acquisition by Chiron.

Gréco is presently a board member of three public companies traded on the NASDAQ, a board member of three private companies, 3 international institutions and is an advisor to World Health Organization (WHO) for vaccine research. Gréco has been president of two French professional associations: the Groupement pour l'Elaboration et la Réalisation de Statistiques (GERS), a market research association, 1980-1983, the Club Interpharmaceutique (CIP), an association in the area of pharmaceutical distribution, 1986-1994, as well as president of the European Vaccine Manufacturers (EVM), 1994-1998 and President of the Biological Committee of the International Federation of Pharmaceutical Industry Associations (1999-2002).

Gréco has written several articles on the vaccine field and has participated in many international conferences. He recently authored a chapter of “New Generation Vaccines,” 3rd edition. He has also taught several French post-graduate courses.

Gréco holds a master’s degree from Institut d'Etudes Politiques de Paris (1965) and an M.B.A. from the University of Western Ontario, Richard IVEY Business School, Canada (1968).
return to top

Richard Meadows
Director
Richard Meadows was the lead partner in a $30.5 million USD investment in TARGEGEN, a San Diego-based company focusing on the mechanism of edema formation in AMI and solid tumors in cancer. There, he shared leadership in financing with William Blair. Meadows has been appointed to four Boards of biotechnology companies, including Argos Therapeutics, THERION Biologics, MOLECULAR MINING and TARGEGEN.

Meadows joined CDP Capital Technology Ventures in 2003 as a Venture Advisor, assisting partners in overseeing and managing their North American investments, as well as making new investments in promising biomedical companies. Prior to that, he was president and CEO of the first Canadian start-up in wound care. He started with a Series-A round of $3.5 million of VC money, and, in collaboration with the Medical Research Council of Canada (MRC), Investments Partnerships Canada, Industry Canada and the Department of Foreign Affairs and International Trade (DFAIT), Meadows created the Life Sciences Research Investments Initiative in 1997.

Meadows has facilitated, developed and wrote strategic plans for the following: a spin-off of the NRC focused on Gap-Junction modulation (PharmaGap (GAP on the TSX Venture Exchange); a new Canadian R&D facility for Cheil Jedang Pharma of Seoul, Korea; a Canadian subsidiary for a multinational French firm (with annual sales of 4+ billion FFr); a major diversification effort by a large healthcare firm into the OTC market; a world-class research institute (Institute of Biomedical Engineering of the University of Toronto); and the Toronto Hospital Research Division.

Additionally, Meadows is a 2004 Board member of the Canadian Biotechnology Human Resources Council; a 2000 appointed representative of the SPEQ, to the Board of BIORTHEX, Inc. He was appointed, Chairman, Audit Committee; a 1999-2000 Member of the Board of Directors, DERMACOR Inc.; a 1995 - 1999 Member of the Board & Human Resources Committee, BIORTHEX, Inc. Montreal, QC; a 1997-1998 Consultant to The Business Development Office, the Medical Research Council of Canada; a 1999- 2000 Business Advisor, EXELLA, Life Sciences Equities, Inc. a VC fund established to invest in genomics projects. He is also an elected member of the Drug Information Association, New York Academy of Sciences, North American Planning Conference, and the Canadian Healthcare Licensing Association.
return to top

Philip R. Tracy, J.D.
Director
Philip R. Tracy was formerly the president and CEO of Burroughs Wellcome Co., a major research-based pharmaceutical company with $1.2 billion in sales and 5,000 employees. Tracy has served on the boards of directors of the Pharmaceutical Research and Manufacturers Association of America and the Nonprescription Drug Manufacturers Association. He also currently serves as chairman of the board of visitors for the Duke University Medical Center. Through 1996, Tracy was a member of the board of visitors for the University of North Carolina at Chapel Hill. He is presently Of Counsel with Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. Tracy is also a venture partner of Intersouth Partners and currently serves on the boards of directors of three Intersouth portfolio companies, two public and one private. He received his B.A. from University of Nebraska and his J.D. from George Washington University.
return to top

Brian J. Underdown, Ph.D.
Director
Brian J. Underdown is currently vice-president, science and technology at MDS Capital Corp. Underdown is also president and chief operation officer of University Medical Discoveries Inc. (UMDI), jointly founded by MDS Capital and the Canadian Medical Discoveries Fund. Prior to joining MDS Capital, he held various senior-level positions in the commercial and academic sectors including assistant vice-president of research, at Pasteur Merieux Connaught. Before that, he was the associate dean of research at McMaster University, Faculty of Health Sciences and the University of Toronto Faculty of Medicine. His primary research interests have been in the field of mucosal immunology and vaccine development. Underdown attended McGill University where he graduated with a B.S. in honors chemistry and a Ph.D. in immunology and undertook post-doctoral studies at Washington University.
return to top

Sander van Deventer, M.D., Ph.D.
Director
Sander van Deventer is Professor of Gastroenterology at the Academic Medical Center in Amsterdam. Dr. van Deventer has held numerous academic appointments and has been the principle clinical investigator for several clinical trials. He has served on a number of regulatory and pharmaceutical industry scientific advisory boards and has been an advisor to the Food and Drug Administration. Dr. van Deventer received his M.D. and Ph.D. from the University of Amsterdam.
return to top